We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2026 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Bifunctional Nanoparticles Show Potential in Cancer Models

By LabMedica International staff writers
Posted on 19 Jun 2017
Image: A photomicrograph showing T-cells (red) and tumor cells (green) incubated with control particles (left) or immunoswitch particles (right). The T-cells that have attached to tumor cells are indicated by green arrows (Photo courtesy of Alyssa Kosmides, Johns Hopkins University).
Image: A photomicrograph showing T-cells (red) and tumor cells (green) incubated with control particles (left) or immunoswitch particles (right). The T-cells that have attached to tumor cells are indicated by green arrows (Photo courtesy of Alyssa Kosmides, Johns Hopkins University).
To be successful, an immunotherapeutic approach for treating cancer must overcome the immunosuppressive effects of the tumor microenvironment; a novel bifunctional nanoparticle does just that.

To counteract the immunosuppressive tumor microenvironment, investigators at Johns Hopkins University (Baltimore, MD, USA) coated 100 nanometers in diameter paramagnetic iron particles with two different kinds of antibodies. The pair of antibodies was crafted to block simultaneously the inhibitory checkpoint PD-L1 (programmed death ligand 1) signal while stimulating T-cells via the 4-1BB co-stimulatory pathway. The investigators coined the term "immunoswitch" to describe these novel bifunctional particles.

The investigators tested immunoswitch therapy in several mouse melanoma and colon cancer models. They reported in the June 7, 2017, online edition of the journal ACS Nano that this treatment significantly delayed tumor growth and extended survival in multiple mouse cancer models in comparison to the use of soluble antibodies or nanoparticles separately conjugated with the inhibitory and stimulating antibodies. The immunoswitch-treated mice developed tumors that were nearly 75% smaller than those in animals that received no treatment, whereas soluble antibody only reduced tumor growth by approximately 25%. Half of immunoswitch-treated mice survived after 30 days, whereas all untreated mice died by day 22.

Immunoswitch particles enhanced effector-target cell conjugation and bypassed the requirement for previous knowledge of tumor antigens. Furthermore, the use of the immunoswitch nanoparticles resulted in an increased density, specificity, and in vivo functionality of tumor-infiltrating CD8+ T-cells.

"Immunotherapies have significant potential and yet room for improvement," said senior author Dr. Jonathan P. Schneck, professor of pathology at Johns Hopkins University. "The improvement here was to make, for the first time, a nanoparticle that can interact simultaneously with multiple types of cells in the complex tumor microenvironment, dramatically increasing its effectiveness. The double-duty immunoswitch particles were clearly more effective than a mixture of nanoparticles that each targeted just one protein and acted in a synergistic fashion, but we do not yet know why. It may be that the immunoswitch particles' success comes from bringing T-cells and their targeted tumor cells into close proximity."

Related Links:
Johns Hopkins University

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Slide Scanner System
NanoZoomer S540MD
Gold Member
Neonatal Heel Incision Device
Tenderfoot

Channels

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more